NCT05185284 is a Phase 3 clinical trial of Favipiravir in COVID-19, sponsored by Promomed, LLC.

Who is sponsoring NCT05185284?

NCT05185284 is sponsored by Promomed, LLC.

What drugs are being tested in NCT05185284?

Interventions in NCT05185284: Favipiravir, Favipiravir, Remdesivir.

Is NCT05185284 still recruiting?

NCT05185284 is currently completed. Last updated 11 January 2022.

Last reviewed 2022-01-11 · How we verify

NCT05185284

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19

Completed Phase 3 Last updated 11 January 2022

What this trial tests

Phase 3 trial testing Favipiravir in COVID-19 in 217 participants. Completed in 30 December 2021.

Timeline

11 August 2021

Primary endpoint
30 December 2021

30 December 2021

Quick facts

Lead sponsor	Promomed, LLC
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	217
Start date	11 August 2021
Primary completion	30 December 2021
Estimated completion	30 December 2021
Sites	6 locations across Russia

Drugs / interventions tested

Favipiravir (FAVIPIRAVIR) — full drug profile →
Favipiravir (FAVIPIRAVIR) — full drug profile →
Remdesivir (remdesivir) — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Promomed, LLC — full company profile →

Who can join

Adults 18 to 80, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is open-labe randomized multicenter comparative Phase III study conducted in 7 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir for parenteral administration compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population.
Chavda VP, Teli D, Balar PC, Vaghela D, et al · · 2023 · cited 3× · PMID 36903575 · DOI 10.3390/molecules28052332

Verify or expand the search:

Other trials of Favipiravir

Trials testing the same drug.

NCT06860334 — UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF · Phase 2 · not yet recruiting
NCT06488300 — Assessing Antiviral Treatments in Early Symptomatic RSV · Phase 2 · recruiting
NCT05940545 — UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF · Phase 1, PHASE2 · unknown
NCT05648448 — A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza · Phase 2 · recruiting
NCT05502081 — Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hos · Phase 4 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Promomed, LLC trials

Trials by the same sponsor.

NCT05722691 — Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis · Phase 3 · completed
NCT05939622 — Efficacy of the Therapy With BRAINMAX® Using fMRI for the Treatment of Patients With Asthenia After COVID-19 · Phase 4 · completed
NCT05689827 — Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After COVID-19 · Phase 4 · completed
NCT05656495 — Efficacy and Safety of Ambervin® and Standard Therapy in Hospitalized Patients With COVID-19 · Phase 3 · completed
NCT05595824 — Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19 · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05185284 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Promomed, LLC
Last refreshed: 11 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05185284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing